Fig. 6

Exosomal lncRNA PART1 promotes gefitinib resistance by activating Bcl-2 signaling pathway. a Histogram shows the fold changes for the activities of different signaling pathways, as indicated by reporter activity. b Western blot analysis showed that knockdown of SNHG14 reversed the effect of exosomal treatment. c TUNEL assay showed that exosome treatment inhibited cell apoptosis levels, but this effect was abrogated by simultaneous treatment of Bcl-2 inhibitor venetoclax. ^**P < 0.01 compared to Exosome group. d Treatment with venetoclax abrogated the PART1-induced gefitinib resistance. ^***P < 0.01 compared to negative control group